Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-responders

NCT07569315 | Not Yet Recruiting Phase 2

• 1 other identifier: Successive/Single GnRH agonist
• Study Type: interventional
• Target: 190
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this randomized controlled study is to compare the efficacy of three successive doses of a GnRH agonist ( administered 36 , 24 and 12 hours before oocyte retrieval ) with a single dose of a GnRH agonist ( administered 36 hours before oocyte retrieval ) in triggering ovulation in hyper-responders

Conditions

Infertility

Keywords

Infertility; GnRH agonist trigger; IVF-ET; Hyper-responders; PCOS

Outcome Measures

Primary Outcomes (1)

• Metaphase-II oocytes rate

  Number of MII oocyte/ number of cumulus oocyte complex

  Ten to fifteen days after starting ovarian stimulation

Secondary Outcomes (2)

• Clinical pregnancy rate

  Five weeks after embryo transfer

• Ongoing pregnancy Rate

  Eighteen weeks after embryo transfer

Study Arms (2)

Successive doses GnRH agonist

EXPERIMENTAL

Three successive doses of GnRH agonist are administered 36 , 24 and 12 hours before oocyte retrieval

Drug: Successive doses GnRH agonist

Single dose GnRH agonist

ACTIVE COMPARATOR

A single dose of GnRH agonist is administered 36 hours before oocyte retrieval

Drug: Single dose GnRH agonist

Interventions

Successive doses GnRH agonist DRUG

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup. Two additional doses of triptorelin ( 0.1 mg / S.C ) are administered subcutaneously 12 and 24 hours after the first dose of GnRH agonist.

Successive doses GnRH agonist

Single dose GnRH agonist DRUG

GnRH agonist ( Triptorelin ) ( 0.2 mg / S.C ) is administered 36 hours before ovum pickup.

Single dose GnRH agonist

Eligibility Criteria

• Age: 18 Years - 40 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• GnRH antagonist IVF cycle
• Hyper-responders to induction of ovulation

You may not qualify if:

• Hypogonadotrophic hypogonadism
• Endometriosis
• History of recurrent abortion

Sponsors & Collaborators

• Bedaya Hospital: lead

Study Sites (1)

Bedaya Hospital

Giza, Egypt

Location

Related Publications (1)

• Hashemi SH, Hafezi M, Arabipoor A, Zareei M, Vesali S, Eftekhari-Yazdi P. Can We Harvest More Mature Oocytes by Repeating Gonadotropin-Releasing Hormone Agonist Doses in Polycystic Ovarian Syndrome Patients at Risk of OHSS in Antagonist Cycles? A Randomised Clinical Trial. Int J Fertil Steril. 2024 Jul 13;18(Suppl 1):48-54. doi: 10.22074/ijfs.2023.2008905.1513.

  PMID: 39033370 BACKGROUND

MeSH Terms

Conditions

Infertility

Interventions

Gonadotropin-Releasing Hormone

Condition Hierarchy (Ancestors)

Genital Diseases; Urogenital Diseases

Intervention Hierarchy (Ancestors)

Pituitary Hormone-Releasing Hormones; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Oligopeptides; Nerve Tissue Proteins; Proteins

Central Study Contacts

Usama M. Fouda, Prof.

CONTACT

+201095401375; umfrfouda@yahoo.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 29, 2026
• First Posted: May 6, 2026
• Study Start (Estimated): June 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): April 1, 2028
• Last Updated: May 6, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)